Cargando…

Radiopharmaceutical Formulation and Preclinical Testing of (68)Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial

The new minigastrin analog DOTA-MGS5 is a promising new candidate for targeting cholecystokinin-2 receptor (CCK2R)-expressing tumors. To enable the clinical translation of PET/CT imaging using (68)Ga-labeled DOTA-MGS5, different quality and safety aspects need to be considered to comply with the reg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hörmann, Anton A., Klingler, Maximilian, Rangger, Christine, Mair, Christian, Decristoforo, Clemens, Uprimny, Christian, Virgolini, Irene J., von Guggenberg, Elisabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235783/ https://www.ncbi.nlm.nih.gov/pubmed/34208516 http://dx.doi.org/10.3390/ph14060575

Ejemplares similares

Automated Synthesis of (68)Ga-Labeled DOTA-MGS8 and Preclinical Characterization of Cholecystokinin-2 Receptor Targeting
por: Hörmann, Anton Amadeus, et al.
Publicado: (2022)

[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging
por: Hennrich, Ute, et al.
Publicado: (2020)

Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
por: Opalinska, Marta, et al.
Publicado: (2023)

Preclinical evaluation of two (68)Ga-siderophores as potential radiopharmaceuticals for Aspergillus fumigatus infection imaging
por: Petrik, Milos, et al.
Publicado: (2012)

Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT
por: Bayerschmidt, Steffen, et al.
Publicado: (2021)

The (68)Ga/(177)Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up
por: Maffey-Steffan, Johanna, et al.
Publicado: (2019)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

Exploiting the Concept of Multivalency with (68)Ga- and (89)Zr-Labelled Fusarinine C-Minigastrin Bioconjugates for Targeting CCK2R Expression
por: Summer, Dominik, et al.
Publicado: (2018)

[(68)Ga]NODAGA-RGD – Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis
por: Haubner, Roland, et al.
Publicado: (2016)

Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUV(max) reference range for management of pancreatic neuroendocrine tumours
por: Virgolini, Irene, et al.
Publicado: (2016)

Prospective of (68)Ga-Radiopharmaceutical Development
por: Velikyan, Irina
Publicado: (2013)

Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle
por: Nilica, Bernhard, et al.
Publicado: (2016)

Good practices for (68)Ga radiopharmaceutical production
por: Nelson, Bryce J. B., et al.
Publicado: (2022)

Preparation and preclinical evaluation of (68)Ga-DOTA-amlodipine for L-type calcium channel imaging
por: Firuzyar, Tahereh, et al.
Publicado: (2016)

Preparation and Biological Study of (68)Ga-DOTA-alendronate
por: Fakhari, Ashraf, et al.
Publicado: (2016)

(68)Ga-Based Radiopharmaceuticals: Production and Application Relationship
por: Velikyan, Irina
Publicado: (2015)

Cold Kit Labeling: The Future of (68)Ga Radiopharmaceuticals?
por: Lepareur, Nicolas
Publicado: (2022)

Preclinical Assessment of a (68)Ga-DOTA-Functionalized Depsipeptide as a Radiodiagnostic Infection Imaging Agent
por: Ebenhan, Thomas, et al.
Publicado: (2017)

Correction: Klingler, M., et al. Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m. Pharmaceuticals 2019, 12, 13
por: Klingler, Maximilian, et al.
Publicado: (2019)

Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m
por: Klingler, Maximilian, et al.
Publicado: (2019)

Effect of N-Terminal Peptide Modifications on In Vitro and In Vivo Properties of (177)Lu-Labeled Peptide Analogs Targeting CCK2R
por: Hörmann, Anton Amadeus, et al.
Publicado: (2023)

Initial Clinical Experience with (68)Ga-DOTA-NOC Prepared Using (68)Ga from Nanoceria-polyacrylonitrile Composite Sorbent-based (68)Ge/(68)Ga Generator and Freeze-dried DOTA-NOC Kits
por: Chandra, Piyush, et al.
Publicado: (2017)

Highly variable biodistribution of (68)Ga labeled somatostatin analogues (68)Ga-DOTA-NOC and (68)Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT
por: Cheng, Monica, et al.
Publicado: (2022)

Adventures in radiosynthesis of clinical grade [(68)Ga]Ga-DOTA-Siglec-9
por: Käkelä, Meeri, et al.
Publicado: (2018)

[(68)Ga]Ga-DOTA-TATE uptake due to COVID-19 vaccination
por: Weiler-Sagie, Michal, et al.
Publicado: (2021)

Physiological Biodistribution of (68)Ga-DOTA-TATE in Normal Subjects
por: Özgüven, Salih, et al.
Publicado: (2021)

Imaging Properties and Tumor Targeting of (68)Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
por: Gruber, Leonhard, et al.
Publicado: (2022)

Comparison of Ga-68-Labeled Fusarinine C-Based Multivalent RGD Conjugates and [(68)Ga]NODAGA-RGD—In Vivo Imaging Studies in Human Xenograft Tumors
por: Zhai, Chuangyan, et al.
Publicado: (2016)

Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy
por: Stenvall, Anna, et al.
Publicado: (2022)

Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE
por: Bruvoll, Ragnar, et al.
Publicado: (2023)

Design of CGMP Production of (18)F- and (68)Ga-Radiopharmaceuticals
por: Chi, Yen-Ting, et al.
Publicado: (2014)

New sensitive method for HEPES quantification in (68)Ga-radiopharmaceuticals
por: Antunes, I. F., et al.
Publicado: (2020)

Good practices for Ga-68 radiopharmaceutical production: an important correction
por: Gültekin, Aziz
Publicado: (2023)

Enhancing Clinical Diagnosis for Patients With Persistent Pulmonary Abnormalities After COVID-19 Infection: The Potential Benefit of (68)Ga-FAPI PET/CT
por: Sviridenko, Anna, et al.
Publicado: (2022)

Head-to-Head Comparison of (68)Ga-DOTA-TATE and (68)Ga-DOTA-JR11 PET/CT in Patients With Tumor-Induced Osteomalacia: A Prospective Study
por: Hou, Guozhu, et al.
Publicado: (2022)

PET-CT imaging of pulmonary inflammation using [(68)Ga]Ga-DOTA-TATE
por: Puuvuori, Emmi, et al.
Publicado: (2022)

Occupational radiation exposure assessment during the management of [(68)Ga]Ga-DOTA-TOC
por: Riveira-Martin, Mercedes, et al.
Publicado: (2022)

Novel Preclinical and Radiopharmaceutical Aspects of [(68)Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer
por: Eder, Matthias, et al.
Publicado: (2014)

Standardized image quality for (68)Ga-DOTA-TATE PET/CT
por: Cox, Christina P. W., et al.
Publicado: (2020)

Current status of theranostics in prostate cancer
por: Virgolini, Irene, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fc6qn7mu5c8kniqjujqk92nhb1